03rd week of 2014 patent applcation highlights part 50 |
Patent application number | Title | Published |
20140018383 | MYELOID DIFFERENTIATION INDUCING AGENTS - Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders. | 2014-01-16 |
20140018384 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE - There is provided compounds of formula I, wherein X | 2014-01-16 |
20140018385 | Identification Of PCNA Targeting Compounds For Cancer Therapy And PCNA Function Regulation - Pharmaceutical compositions and methods for inhibiting cell growth, modulating function of PCNA, treating prostate cancer, and enhancing PCNA trimer formation are disclosed. The methods include administering an effective amount of a compound of Formula (I), Formula (II) | 2014-01-16 |
20140018386 | LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT - The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent. Also provided are processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. Also provided is a method for treating a subject afflicted with a form of multiple sclerosis (MS) or for alleviating a symptom of MS in a subject afflicted with a form of MS comprising administering to the subject a stable pharmaceutical composition as described herein. Also provided is use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of MS or for alleviating a symptom of MS in a subject afflicted with a form of multiple MS. | 2014-01-16 |
20140018387 | OINTMENT WITH EXCELLENT FORMULATION STABILITY - Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene•3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant. | 2014-01-16 |
20140018388 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS - A compound of formula | 2014-01-16 |
20140018389 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 2014-01-16 |
20140018390 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES - The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents. | 2014-01-16 |
20140018391 | Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content - The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms. | 2014-01-16 |
20140018393 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS - This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer. | 2014-01-16 |
20140018394 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases. | 2014-01-16 |
20140018395 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2014-01-16 |
20140018396 | COMBINATION OF SULFONAMIDE COMPOUND - The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and/or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug. | 2014-01-16 |
20140018397 | Sustained Release Aminopyridine Composition - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2014-01-16 |
20140018398 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY - The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 2014-01-16 |
20140018399 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 2014-01-16 |
20140018400 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS - In one aspect, the invention relates to compounds having a general structure: and methods of using same to modulate calcium release. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-01-16 |
20140018401 | CYTOCHROME P450 INHIBITORS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) | 2014-01-16 |
20140018402 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION - The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops. | 2014-01-16 |
20140018403 | NO-RELEASING GUANIDINE-COXIB ANTI-CANCER AGENTS - The present disclosure provides NO-releasing guanidine-coxib anti-cancer agents, having the structure of Formula (I): | 2014-01-16 |
20140018404 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF - Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders. | 2014-01-16 |
20140018405 | Anticancer Compounds - The invention describes dual Aurora kinase/MEK inhibitors and their use in therapy. | 2014-01-16 |
20140018406 | Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration - Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer. | 2014-01-16 |
20140018407 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 2014-01-16 |
20140018408 | OLIGONUCLEOTIDES FOR TREATING INFLAMMATION AND NEOPLASTIC CELL PROLIFERATION - There is provided oligonucleotides directed against the CCR3 receptor and the common beta sub-unit of IL-3, IL-5 and GMCSF receptors. The oligonucleotides are useful to inhibit general inflammation, including inflammation associated with asthma, COPD, allergy, Cystic fibrosis (CF), hypereosinophilia and neoplastic cell proliferation such as cancer. | 2014-01-16 |
20140018409 | Method for Determining Hepatocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells - Described herein are methods of determining an HCC subtype in a subject which includes a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. Also described are methods of detecting HCC stem cells in a sample, and methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells. | 2014-01-16 |
20140018410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KLF-1 AND BCL11A GENES - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the KLF1 gene and the BCL11A gene, and methods of using such dsRNA compositions to inhibit expression of KLF1 and BCL11 A, respectively. | 2014-01-16 |
20140018411 | Methods for Diagnosing Prostate Cancer using MicroRNAs - Described herein are methods for diagnosing prostate cancer using microRNAs. Also described are methods and compositions for the diagnosis and treatment of solid cancers. Methods of identifying inhibitors of tumorigenesis are also provided. | 2014-01-16 |
20140018412 | Methods for Diagnosing Lung Cancer using MicroRNAs - Described herein are methods for diagnosing lung cancer using microRNAs. Also described are methods and compositions for the diagnosis and treatment of solid cancers. Methods of identifying inhibitors of tumorigenesis are also provided. | 2014-01-16 |
20140018413 | MIRNA LENTIVIRUS VECTOR - A miRNA lentivirus vector including a sequence No. 11. The vector is capable of improving the fertility of animals by inhibiting the expression of inhibin of animals. | 2014-01-16 |
20140018414 | METHODS OF INDUCING ANESTHESIA - The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. | 2014-01-16 |
20140018415 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 2014-01-16 |
20140018416 | THERAPEUTIC AGENT FOR CORNEAL SENSORY NERVE DAMAGE CONTAINING SEMAPHORIN INHIBITOR AS ACTIVE INGREDIENT - A compound represented by formula (1), or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves: | 2014-01-16 |
20140018417 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES - A method for manufacturing a compound represented by the formula (13): | 2014-01-16 |
20140018418 | METHODS OF TREATING OR PREVENTING H5N1 INFLUENZA - A method of treating or preventing H5N1 influenza by administering to a person in need thereof a pharmacologically effective amount of 5-acetamido-4-guanidino-9-O-hexanoyl-2,3,4,5-tetradeoxy-7-O-methyl-D-glycero-D-galacto-non-2-enopyranosoic acid, 5-acetamido-4-guanidino-9-O-decanoyl-2,3,4,5-tetradeoxy-7-O-methyl-D-glycero-D-galacto-non-2-enopyranosoic acid, 5-acetamido-4-guanidino-9-O-dodecanoyl-2,3,4,5-tetradeoxy-7-O-methyl-D-glycero-D-galacto-non-2-enopyranosoic acid or 5-acetamido-4-guanidino-9-O-tetradecanoyl-2,3,4,5-tetradeoxy-7-O-methyl-D-glycero-D-galacto-non-2-enopyranosoic acid. A method of preventing H5N1 influenza by administering to a person in need thereof a pharmacologically effective amount of 5-acetamido-4-guanidino-9-O-octanoyl-2,3,4,5-tetradeoxy-7-O-methyl-D-glycero-D-galacto-non-2-enopyranosoic acid. | 2014-01-16 |
20140018419 | TRI-SALT FORM OF METFORMIN - Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity. | 2014-01-16 |
20140018420 | FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy. | 2014-01-16 |
20140018421 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 2014-01-16 |
20140018422 | DERIVATIVES OF TETRACAINE - Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases. | 2014-01-16 |
20140018423 | ANTIMICROBIAL AGENT COMPRISING A CYSTEINE COMPONENT COVALENTLY BOUND TO A SUBSTRATE IN PARTICULAR BY BINDING THROUGH AN S-S BRIDGE VIA A SPACER MOLECULE - The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm. | 2014-01-16 |
20140018424 | PREVENTIVE EFFECT OF CITRULLINE ON THE SPONTANEOUS DEVELOPMENT OF TUMORS - L-citrulline or a nutraceutically or pharmaceutically acceptable salt thereof for reducing the kinetics of tumour development or reduce the incidence of tumours in aged humans and animals. | 2014-01-16 |
20140018425 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 2014-01-16 |
20140018426 | FOOD OR BEVERAGE COMPOSITION FORTIFIED WITH THYRONAMINES AND/OR THYRONAMINE PRECURSORS - Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of T2, T1AM, and/or T0AM in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being. | 2014-01-16 |
20140018427 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 2014-01-16 |
20140018428 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 2014-01-16 |
20140018429 | PROTECTION OF NORMAL CELLS - The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms. | 2014-01-16 |
20140018430 | NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS - The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells. | 2014-01-16 |
20140018431 | TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA - The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 2014-01-16 |
20140018432 | ELECTROCHEMICAL GENERATION OF CHLORINATED UREA DERIVATIVES - Method of single step electrochemical generation of chlorinated urea, chlorinated dimethylurea and other chlorourea derivatives is disclosed. The chlorinated species are generated in situ and upon demand and can be used for microbial control in industrial water treatment. | 2014-01-16 |
20140018433 | METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) - This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention. | 2014-01-16 |
20140018434 | CLEANING, INSECTICIDE, INSECT REPELLANT, GLUE SOLVENT AND ANTI-IRRITATION COMPOSITION - Exemplary embodiments of the present invention relate to pesticides, insecticides, insect repellant, insect anti-feeding, cleaning, glue dissolving and anti-irritation and wound healing compositions for humans and animals and, more particularly, to such compositions which are effective in killing, removing and/or repelling a wide range of endoparasites, ectoparasites and insects while also being non-toxic to humans, animals, and the environment. An exemplary embodiment of the present invention is directed to an aqueous composition including a mixture of at least one ethanolamide and at least one esterified fatty acid. Another exemplary embodiment of the present invention is directed to an aqueous composition including at least one esterified fatty acid in water and at least one emulsifier. The aqueous compositions may be used as a cleaning composition, insecticide, insect repellant, glue solvent or to relieve irritation from and/or promote healing of insect bites, skin abrasions superficial burns and wounds. | 2014-01-16 |
20140018435 | Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers - The invention provides for compositions for transdermal delivery of a therapeutic agent associated with a surface modified poly(amidoamine) PAMAM dendrimer, wherein the surface modified dendrimer increased skin penetration of the therapeutic agent. The invention particularly provides for compositions and methods for transdermal delivery of anticancer and chemo-preventive agents. | 2014-01-16 |
20140018436 | DEUTERIUM-ENRICHED BUPROPION - The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2014-01-16 |
20140018437 | TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS - Disclosed herein is a composition comprising of resveratrol and/or derivatives thereof and/or functionally related compounds and benzoyl peroxide and/or derivatives thereof and/or functionally related compounds for the treatment of acne and other inflammatory or infectious skin disorders. Also disclosed are methods of treating acne and other inflammatory and infectious skin disorders using the compositions described herein. | 2014-01-16 |
20140018438 | METHOD OF DESTROYING BACTERIAL BIOFILM USING STERILE INTRAVENOUS OR INTRACAVERNOUS GLYCERIN - Disclosed is a method of preventing or inhibiting biofilm formation by a population of bacteria comprising the administration of a sterile intravenous normal saline solution containing glycerin and amino acids. In some embodiments, the concentration of glycerin in the normal saline solution is approximately 3%. In some embodiments, the concentration of amino acids in the normal saline solution is approximately 3%. In some embodiments, the intravenous solution is administered for 48 hours at 80 cc/hour. In some embodiments, the solution is infused via intracavernous administration into an infected body cavity. | 2014-01-16 |
20140018439 | Weather-Resistant Pearlescent Pigments, Process for the Production and Use Thereof - The present invention relates to a weather-resistant pearlescent pigment which consists of a platelet-shaped substrate coated with one or more highly refractive metal oxides, the platelet-shaped substrate being selected from the group consisting of synthetic mica flakes, glass flakes, SiO | 2014-01-16 |
20140018440 | MEDICAL DEVICES HAVING POLYMER BRUSHES - According to an aspect of the present invention, internal medical devices are provided, which contain at least one surface region that comprises a polymer brush. The polymer brush, in turn, contains one or more types of hydrophobic polymer chains and one or more types of hydrophilic polymer chains. | 2014-01-16 |
20140018441 | Methods and Apparatus for Assembly - In exemplary implementations of this invention, hierarchical, nanometer-precise assembly is performed: A first structural unit is attached to a solid substrate in a first fluidic flow. A second structural unit is attached to the first structural unit in a second fluidic flow, a third structural unit is attached to the second structural unit in a third fluidic flow, and so on, until a target structure comprising the structural units is assembled. The first, second, third and so on fluidic flows are separate and occur in order in a temporal sequence. During the temporal sequence, a specific permutation of nucleobases is used repeatedly, in separate fluidic flows which occur at different times, to form multiple attachments between structural units in an assembly. The assembled target structure is removed from the solid substrate. Attachments between the structural units may be formed by nucleobase pairing. | 2014-01-16 |
20140018442 | NOVEL STABILIZED CAROTENOID COMPOSITIONS - The present invention relates to novel compositions containing finely dispersed carotenoids. The novel compositions of this invention can be used as colorants or additives for food, beverages, animal feeds, cosmetics or drugs. The colorant composition may be a liquid or a solid composition. The solid composition comprises at least one carotenoid which is dispersed in a matrix, wherein the matrix contains at least one carbohydrate and/or one modified carbohydrate and optionally, a protein, a modified protein or mixtures thereof, wherein the at least one carbohydrate and/or one modified carbohydrate is starch or modified starch, wherein the amount of starch or modified starch is from about 10 wt-% to 60 wt-% of based on the total weight of the matrix, and wherein the concentration of the at least one carotenoid is at least 2% based on the total weight of the composition. Preferably β-carotene is used as a solid water-dispersible colorant composition. | 2014-01-16 |
20140018443 | VESICLE COMPOSITION - The present invention is to provide a vesicle composition comprising the following components (A), (B) and (C):
| 2014-01-16 |
20140018444 | Water-In-Oil Emulsified Cosmetic - The present invention provides a water-in-oil emulsion cosmetic that is excellent in the resilient and supple (in other words, firm and tensional) feels and also excellent in the moisturizing effect and feeling in use. The water-in-oil emulsion cosmetic of the present invention is characterized by comprising the following (A) to (D):
| 2014-01-16 |
20140018445 | METHOD FOR DETECTION OF PATHOGENIC ORGANISMS - A method for detection of pathogenic organisms wherein the method includes differentiation between species. The method is especially suitable to detect and to diagnose infection by pathogenic organisms which are hard and/or laborious to detect with conventional methods. The method relies upon analysis of specific variable regions of the RNase P RNA gene, namely the P3 and/or P19 region(s). | 2014-01-16 |
20140018446 | Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease - Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased. | 2014-01-16 |
20140018447 | METHODS OF DIAGNOSING AND TREATING INTESTINAL GRANULOMAS AND LOW BONE DENSITY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD). | 2014-01-16 |
20140018448 | ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE - The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. | 2014-01-16 |
20140018449 | METHOD FOR PRODUCING HYDROCARBONS - A method for producing hydrocarbons includes: a synthesis step of synthesizing hydrocarbons by the Fischer-Tropsch synthesis reaction using a slurry bubble column reactor having a slurry containing catalyst particles and liquid hydrocarbons retained inside the reactor, and having a gas phase portion located above the slurry; a discharging step of passing the slurry through a filter positioned inside and/or outside the reactor, thereby separating and discharging the heavy liquid hydrocarbons; a backwash step of flushing liquid hydrocarbons through the filter in the opposite direction to the flow of the slurry, thereby returning the catalyst particles to the reactor; and a cooling and gas-liquid separation step of cooling the hydrocarbons discharged from the gas phase portion, and then separating and collecting the condensed light liquid hydrocarbons. The liquid hydrocarbons flushed through the filter in the backwash step include the light liquid hydrocarbons obtained in the cooling and gas-liquid separation step. | 2014-01-16 |
20140018450 | METHOD OF SUPPRESSING METAL CONTAMINATION OF SYNTHESIS GAS PRODUCTION APPARATUS - A synthesis gas production apparatus (reformer) to be used for a synthesis gas production step in a GTL (gas-to-liquid) process is prevented from being contaminated by metal components. A method of suppressing metal contamination of a synthesis gas production apparatus operating for a GTL process that includes a synthesis gas production step of producing synthesis gas by causing natural gas and gas containing steam and/or carbon dioxide to react with each other for reforming in a synthesis gas production apparatus in which, at the time of separating and collecting a carbon dioxide contained in the synthesis gas produced in the synthesis gas production step and recycling the separated and collected carbon dioxide as source gas for the reforming reaction in the synthesis gas production step, a nickel concentration in the recycled carbon dioxide is not higher than 0.05 ppmv. | 2014-01-16 |
20140018451 | Monolithic Reactor - A monolith catalyst carrier for insertion in a tube of a tubular reactor has a container for holding a monolith catalyst in use. The container has a bottom surface closing the container and a skirt extending upwardly from the bottom surface of the container to a position below the location of a seal and spaced therefrom. The skirt is positioned such that there is a space between an outer surface of the monolith catalyst and the skirt. A seal is located at or near a top surface of the monolith catalyst and extends from the monolith catalyst by a distance which extends beyond an outer surface of the skirt. | 2014-01-16 |
20140018452 | CATALYSTS FOR THE CONVERSION OF SYNTHESIS GAS TO ALCOHOLS - A catalyst suitable for manufacturing a mixture of alcohols from synthesis gas comprises a combination of nickel, two or more metals selected from ruthenium, palladium, gold, chromium, aluminum and tin, and at least one of an alkali metal or alkaline earth series metal as a promoter. The catalyst may be used in a process for converting synthesis gas wherein the primary product is a mixture of ethanol (EtOH), propanol (PrOH), and butanol (BuOH), optionally in conjunction with higher alcohols. | 2014-01-16 |
20140018453 | CATALYSTS FOR THE CONVERSION OF SYNTHESIS GAS TO ALCOHOLS - A catalyst for manufacturing a mixture of alcohols from synthesis gas comprises a combination of nickel, molybdenum, at least one metal selected from the group consisting of palladium, ruthenium, chromium, gold, zirconium, and aluminium, and at least one of an alkali metal or alkaline earth series metal as a promoter. The catalyst may be used in a process for converting synthesis gas wherein the primary product is a mixture of ethanol (EtOH), propanol (PrOH), and butanol (BuOH), optionally in conjunction with higher alcohols. | 2014-01-16 |
20140018454 | ACTIVATED FISCHER-TROPSCH SYNTHESIS REACTION CATALYST AND METHOD FOR PRODUCING HYDROCARBONS - A Fischer-Tropsch synthesis reaction catalyst includes a catalyst support containing a silica and zirconium oxide in an amount of 0.5 to 14% by mass based on the mass of the catalyst support, and cobalt metal and a cobalt oxide supported on the catalyst support in an amount equivalent to 10 to 40% by mass of tricobalt tetroxide based on the mass of the catalyst, wherein the degree of reduction of the cobalt atoms is within a range from 75 to 93%, and the amount of hydrogen gas adsorption per unit mass of the catalyst at 100° C. is within a range from 0.40 to 1.0 ml/g. | 2014-01-16 |
20140018455 | Phosphide Catalyst for Syngas Conversion and the Production Method and Use thereof - This invention provides a phosphide catalyst for syngas conversion and the production method and use thereof, more specifically, to a catalyst for converting a syngas raw material into oxygenates, comprising one or more metallic Fe, Co, Ni and their phosphides, the production method of the catalyst and its use in the reaction of converting a syngas raw material into hydrocarbons and oxygenates. According to the invention, a catalyst for converting H | 2014-01-16 |
20140018456 | PROCESS FOR PREPARING FORMIC ACID - Process for obtaining formic acid by thermal separation of a stream comprising formic acid and a tertiary amine (I), in which a liquid stream comprising formic acid and tertiary amine (I) is produced by combining tertiary amine (I) and a formic acid source, secondary components comprised therein are separated off, formic acid is removed by distillation from the resulting liquid stream in a distillation apparatus, where the bottom output from the distillation apparatus is separated into two liquid phases, and the upper liquid phase is recirculated to the formic acid source and the lower liquid phase is recirculated to the separation of the secondary components and/or to the distillation apparatus, wherein low boilers are removed by distillation from the upper liquid phase and recirculated to the depleted stream. | 2014-01-16 |
20140018457 | Expandable Functional TFE Copolymer Fine Powder, Expanded Products and Reacted Products Therefrom - A functional TFE copolymer fine powder is described, wherein the TFE copolymer is a polymer of TFE and at least one functional comonomer, and wherein the TFE copolymer has functional groups that are pendant to the polymer chain. The functional TFE copolymer fine powder resin is paste extrudable and expandable. Methods for making the functional TFE copolymer are also described. The expanded functional TFE copolymer material may be post-reacted after expansion. | 2014-01-16 |
20140018458 | METHOD FOR PRODUCING o-PHTHALATE POLYESTER POLYOLS WITH LOW CYCLIC ESTER CONTENT - A method for producing a polyester polyol is disclosed. The method comprises reacting phthalic anhydride with a diol selected from the group consisting of ethylene glycol, propylene glycol, 1,3-propanediol, 2-meth-1,3-propanediol, neopentyl glycol, 1,6-hexanediol, polyethylene glycols having a number average molecular weight within the range of 200 g/mol to 600 g/mol, and mixtures thereof at a diol to phthalic anhydride molar ratio within the range of 1.1 to 1.6. The resulting o-phthalate polyester polyol has a hydroxyl value in the range of 18 to 400 mg KOH/g, an acid value in the range of 0.2 to 5.0 mg KOH/g, and 1 wt. % or less of cyclic esters. | 2014-01-16 |
20140018459 | METHOD FOR PRODUCING SHORT-CHAIN POLYFUNCTIONAL POLYETHER POLYOLS UTILIZING SUPERACID AND DOUBLE-METAL CYANIDE CATALYSIS - A two stage alkoxlyation process for preparing a short-chain polyether polyol from a starter compound comprising from 3 to 9 hydroxyl groups and at least one alkylene oxide, wherein said starter compound has a hydroxy equivalent weight of from 22 to 90 Da. Said process comprises a first stage alkoxlyation using a superacid catalyst to prepare an oligomeric alkoxylated starter compound that is further alkoxylated to the short-chain polyether polyol of the invention in a second stage using a DMC catalyst. The process of the present invention may be performed continuously, in a batch, or semi-batch process. | 2014-01-16 |
20140018460 | COMPOSITIONS FOR IMPROVING POLYESTERS - A method for altering the melt characteristics of a polyester, such as the melt strength, the method comprising the step of melt mixing the polyester, with a tetracarboxylic dianhydride; across-linker and chain extender comprising at least two groups being able to react with a carboxy group and a phenolic hydroxyl group; and a poly functional compound comprising at least two groups selected from the group consisting of non-sterically hindered phenolic hydroxyl groups, and carboxy groups. | 2014-01-16 |
20140018461 | PHOTO-LATENT TITANIUM-OXO-CHELATE CATALYSTS - A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R | 2014-01-16 |
20140018462 | METHOD FOR PRODUCING ETHYLENE-VINYL ALCOHOL COPOLYMER RESIN, ETHYLENE-VINYL ALCOHOL COPOLYMER RESIN, AND LAMINATE - Provided are a method for producing an EVOH resin having sufficient long-run workability in melt molding and enabling prevention of coloring such as yellowing, an EVOH resin obtained by this method for production, and a laminate obtained from this resin. Additionally, a method for producing an ethylene-vinyl alcohol copolymer resin capable of efficiently drying while inhibiting deterioration of qualities is provided. The method for producing an ethylene-vinyl alcohol copolymer resin of the present invention includes a step of irradiation with an infrared ray for irradiating with an infrared ray an ethylene-vinyl alcohol copolymer or an ethylene-vinyl ester copolymer that is a precursor of the ethylene-vinyl alcohol copolymer. | 2014-01-16 |
20140018463 | MODIFICATION OF BIOMEDICAL POLYMERS FOR PREVENTION OF FOULING AND CLOTTING - A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting. Short trichlorosilane surface modifiers allow films to be deposited onto poly(ethylene terephthalate), polycarbonate, polypropylene, polyvinyl chloride, polyurethane, and other polymers activated using plasma. | 2014-01-16 |
20140018464 | SILICONE RUBBER-BASED CURABLE COMPOSITION, METHOD FOR PRODUCING SILICONE RUBBER, SILICONE RUBBER, MOLDED ARTICLE, AND TUBE FOR MEDICAL USE - The present invention provides a silicone rubber-based curable composition with which a silicone rubber having excellent tensile strength and tear strength is obtained, a method for producing a silicone rubber using the silicone rubber-based curable composition, a silicone rubber, a molded article using the silicone rubber, and a tube for medical use formed from the molded article. The silicone rubber-based curable composition of the present invention is characterized in that it includes a vinyl group-containing organopolysiloxane (A), an organohydrogen polysiloxane (B), silica particles (C), a silane coupling agent (D), and platinum or a platinum compound (E). | 2014-01-16 |
20140018465 | High Water Content Silicone Hydrogel Contact Lenses - Silicone hydrogel contact lenses having a high water content are described. The lenses are derived from a polymerizable composition including a first siloxane monomer represented by formula (1): | 2014-01-16 |
20140018466 | SELF-RENEWING HYDROPHILIC ORGANIC COATINGS - Hydrophilic coaling compositions and methods to make and use the compositions are disclosed. The compositions include a polymer comprising a plurality of isocyanate groups and a blocking agent contacting at least one of the plurality of isocyanate groups. | 2014-01-16 |
20140018467 | COMPOSITIONS CONTAINING SULFONIC ACID CATALYSTS AND METHODS FOR THE PREPARATION AND USE OF THE COMPOSITIONS - A composition is capable of curing via condensation reaction. The composition uses a sulfonic acid condensation reaction catalyst. The sulfonic acid condensation reaction catalyst is used to replace conventional tin catalysts. The composition can react to form a gum, gel, or rubber. | 2014-01-16 |
20140018468 | FOUNDRY BINDER SYSTEMS - The present invention relates to foundry binder systems forming a curable polyurethane with a catalytically effective amount of a curing catalyst, comprising at least one phenolic resin component comprising at least: a phenolic resin and a solvent of triacetin type and a polyisocyanate component. The invention also relates to foundry mixtures prepared from the binder and an aggregate, to foundry forms such as cores and molds prepared via the no-bake or cold-box processes, and also to the respective processes. The foundry forms obtained by the present invention are especially used for manufacturing metallic components, especially for the casting of metallic components. | 2014-01-16 |
20140018469 | COMPOSITE MATERIAL CONTAINING CARBON NANOTUBES AND PARTICLES HAVING A CORE-SHELL STRUCTURE - A composite material including, in a polymeric composition, carbon nanotubes combined with particles having an elastomeric core and at least one thermoplastic shell. The composite material including, in a polymer composition, carbon nanotubes associated, so as to form aggregations of less than 30 μm, with particles having a core made of totally or partially crosslinked elastomer and at least one thermoplastic shell, in a weight ratio of the particles of core-shell structure to the nanotubes of between 0.5:1 and 2.5:1. Also, a method for preparing said material, as well as to the use thereof for imparting various properties to polymeric matrices. | 2014-01-16 |
20140018470 | SILICA COMPOSITION - The purpose of the present invention is to provide an additive for a solvent-based coating material which has high coating material product stability when added to a solvent-based coating material and whereby the resulting coating film has excellent abrasion resistance. | 2014-01-16 |
20140018471 | OLIGOMERIC PHOSPHONATES AND COMPOSITIONS INCLUDING THE SAME - Disclosed are oligomeric phosphonates including oligophosphonates, random or block co-oligo(phosphonate ester)s and co-oligo(phosphonate carbonate)s produced using a condensation process terminated with hydroxyl, epoxy, vinyl, vinyl ester, isopropenyl, isocyanate groups, and the like. These materials can be used as a reactive additive to other polymers, oligomers or monomer mixtures to impart flame resistance without diminishing melt processability which is important in the fabrication of polymers for many applications. | 2014-01-16 |
20140018472 | EPOXY RESIN COMPOSITIONS COMPRISING EPOXY AND VINYL ESTER GROUPS - Epoxy resin composition comprising
| 2014-01-16 |
20140018473 | AQUEOUS LATEX COATING COMPOSITIONS - Disclosed are aqueous latex-based coating compositions which comprise a blend of an ethylene-vinyl acetate emulsion copolymer component and a selected type of acrylic emulsion copolymer component. The acrylic copolymer component comprises primarily acrylate ester co-monomers or acrylic ester co-monomers and vinyl aromatic, e.g., styrene, co-monomers. The blend of these two emulsion copolymer types also contains a specific type of hydrazine-based, water-soluble cross-linking agent which can eventually react with the acrylic emulsion copolymer component. The acrylic emulsion copolymer is one which contains minor amounts of both 1) carboxy functional co-monomers such as itaconic and/or (meth)acrylic acids, and 2) keto- or aldehyde-containing co-monomers such as diacetone acrylamide. Such latex-based coating compositions can be formulated in the form of water-based paint compositions. These paint products provide paint coatings that exhibit desirable dry and wet adhesion characteristics and desirable resistance to blocking. | 2014-01-16 |
20140018474 | COMPOSITION FOR ANTI-SCRATCH AND WEAR-RESISTANCE PROPERTIES, METHOD OF PREPARING THE SAME, AND ITS APPLICATIONS - Provided are a composition for anti-scratch and wear-resistance properties, a method of preparing the same, and its application. The composition has inorganic particles, a dispersant and an organic binding agent. The inorganic particles are spherical and have an average particle size ranging from 10 nanometers to 999 nanometers. The dispersant has an inorganic dispersant and a polymer dispersant. The specific gravity of the inorganic particles and inorganic dispersant are respectively represented by s1 and s2, 0.052014-01-16 | |
20140018475 | HIGH GLASS TRANSITION TEMPERATURE THERMOSET AND METHOD OF MAKING THE SAME - A process for preparing a nanocomposite includes combining a resin and silsesquioxane; introducing a curing agent to the resin and silsesquioxane to form a composition; and forming a reaction product of the composition to prepare the nanocomposite, wherein a total amount of the silsesquioxane and curing agent in the composition is from 1 wt % to 70 wt %, based on a weight of the composition. Additionally, a process for preparing an article includes combining an epoxy resin and silsesquioxane; introducing a curing agent to the epoxy resin and silsesquioxane to form a composition; and reacting the epoxy resin, silsesquioxane, and curing agent to form the nanocomposite, wherein a molar ratio of a number of moles of an epoxy functional group of the epoxy resin to the sum of the number of moles of the silsesquioxane and curing agent is from 1:1 to 100:1. An article includes the reaction product of the resin, silsesquioxane, and curing agent. | 2014-01-16 |
20140018476 | BUOYANCY CONTROL MATERIAL FOR SUBSEA MAIN PIPELINES AND HIGH-DENSITY BUOYANCY CONTROL MATERIAL FOR SUBSEA MAIN PIPELINES - The buoyancy control material for subsea main pipelines and high-density buoyancy control material for subsea main pipelines are suggested predominantly for use while manufacturing pipes for subsea pipeline installations. Creation of a buoyancy control material with a density greater than 2800 kg/m | 2014-01-16 |
20140018477 | EXTRUSION MOLDING HYDRAULIC COMPOSITION - A hydraulic composition comprising a water-soluble hydroxyalkyl alkyl cellulose, cement, aggregate, reinforcing fibers, and water is provided. The hydroxyalkyl alkyl cellulose has a degree of alkyl substitution of 1.2-1.7, the sum of the degree of alkyl substitution and the molar substitution of hydroxyalkyl is 1.5-2.0, and a proportion of glucose ring not substituted with alkyl and hydroxyalkyl groups per glucose ring unit is up to 10 mol %. The composition cures within a short time and is extrusion moldable even at elevated temperature. | 2014-01-16 |
20140018478 | POLYPROPYLENE RESIN COMPOSITION - A polypropylene-based resin composition including 100 parts by weight of the following component (A), 18 parts by weight or more and 65 parts by weight or less of the following component (B), 6 parts by weight or more and 45 parts by weight or less of the following component (C), 25 parts by weight or more and 60 parts by weight or less of the following component (D), 0.1 part by weight or more and 6.5 parts by weight or less of the following component (E) and 0.15 part by weight or more and 5.0 parts or less by weight of the following component (F): | 2014-01-16 |
20140018479 | RUBBER COMPOSITION AND MANUFACTURING PROCESS THEREFOR, AND TIRE - A rubber composition that can obtain a rubber elastic body having small rolling resistance and excellent impact resilience and a method for producing the same, and a tire having small rolling resistance and excellent impact resilience are provided. | 2014-01-16 |
20140018480 | CARBON FIBER COMPOSITION INCLUDING GRAPHENE NANO-POWDER AND FABRICATION METHOD FOR CARBON FIBER USING THE SAME - The present disclosure relates to a carbon fiber composition and a fabrication method for high-performance carbon fiber using the same. The method can fabricate high-performance carbon fiber (or graphite fiber) with lowering a graphitization temperature by using graphene carbon fiber composition including nano-sized graphene. | 2014-01-16 |
20140018481 | ADVANCED HALOGEN FREE FLAME RETARDANT COMPOSITION FOR HEAT SHRINKABLE MATERIAL AND METHOD OF MAKING THE SAME - A method and composition for a halogen free flame retardant heat shrinkable tube is described. These instant compositions when used to make the heat shrinkable tube products, they improve longitudinal direction shrinkage, mechanical properties, radial direction shrinkage, tube extruding speed, under beam cross-linking process, uniformity of tube thickness, shape and surface without deterioration of flame retardancy. The instant compositions are especially suitable for thin-wall halogen free flame retardant heat shrinkable tube products which are cross-linked by electron beam radiation process. | 2014-01-16 |
20140018482 | POLYMER THICK FILM SOLDER ALLOY/METAL CONDUCTOR COMPOSITIONS - This invention provides a polymer thick film conductor composition comprising (a) a solder alloy powder selected from the group consisting of (i) a tin, silver, and copper alloy powder, (ii) a fin and bismuth alloy powder, and (iii) mixtures thereof, (b) a metal selected from the group consisting of silver, copper, gold, aluminum and mixtures thereof, and (c) an organic medium comprising a thermoplastic resin dissolved in an organic solvent, wherein the solder alloy powder and the metal are dispersed in the organic medium. | 2014-01-16 |
20140018483 | METHOD FOR PRODUCING CERAMIC OR METAL COMPONENTS BY MEANS OF POWDER INJECTION MOULDING, BASED ON THE USE OF INORGANIC FIBRES OR NANOFIBRES - The invention first relates to a feedstock for PIM, including a metal or ceramic powder; a polymeric binder; metallic or ceramic fibres or nanofibres, the fibres or nanofibres being metallic when the powder is metallic, and the fibres or nanofibres being ceramic when the powder is ceramic. It also relates to the method for producing such a feedstock, as well as the method for producing parts by means of powder injection moulding (PIM) using said feedstock. | 2014-01-16 |